Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Net Income (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Net Income for 4 consecutive years, with -$54.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income fell 28.96% to -$54.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$242.7 million, a 50.5% decrease, with the full-year FY2024 number at -$235.8 million, down 56.04% from a year prior.
  • Net Income was -$54.9 million for Q3 2025 at Centessa Pharmaceuticals, down from -$50.3 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$24.9 million in Q2 2023 to a low of -$111.3 million in Q4 2024.
  • A 4-year average of -$49.0 million and a median of -$43.8 million in 2024 define the central range for Net Income.
  • Peak YoY movement for Net Income: skyrocketed 61.51% in 2023, then crashed 202.22% in 2024.
  • Centessa Pharmaceuticals' Net Income stood at -$43.2 million in 2022, then increased by 14.68% to -$36.8 million in 2023, then plummeted by 202.22% to -$111.3 million in 2024, then skyrocketed by 50.69% to -$54.9 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Net Income are -$54.9 million (Q3 2025), -$50.3 million (Q2 2025), and -$26.1 million (Q1 2025).